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 The term glaucoma describes a heterogeneous group of
optic neuropathies that lead to optic nerve atrophy and perma-
nent loss of vision, affecting over 67 million subjects world-
wide [1]. Since glaucoma rates rise exponentially with age,
more glaucoma cases are expected in the future as the western
population gets older [2]. The disease is insidious. Affected
patients frequently have no symptoms, especially in the initial
stages. When detected early, most cases can be successfully
treated with medications, laser treatment, or surgery.
The hereditary forms of glaucoma are genetically hetero-
geneous. Primary open angle glaucoma (POAG) of adult on-
set is the most common form of glaucoma, representing ap-
proximately half of all cases. Normal tension glaucoma (NTG)
is an important subtype of POAG, accounting for approxi-
mately 20-50% of all POAG cases. Patients with NTG show
intraocular pressures that are within the statistical normal range
of the population (10-20 mmHg).
Despite the rather high prevalence and heritable nature of
POAG, identification of causative genes has proven to be dif-
ficult. Though at least 20 loci have been linked to POAG [3],
only two disease-causing genes for POAG have been identi-
fied until lately. A number of studies confirmed that about 4%
of POAG cases show mutations in the MYOC gene [4]. Al-
though mutations in the optineurin gene (OPTN) were initially
reported in 16.7% of families with hereditary POAG [5], sev-
eral other studies have indicated that OPTN sequence variants
are only a rare cause of POAG or NTG [6-8]. Recently, a new
locus for POAG (GLC1G) and the disease-causing gene
(WDR36) have been identified by Monemi and coworkers [9].
In their study, mutation analysis of WDR36 in 130 unrelated
affected individuals revealed a total of 25 allelic variants. The
function of WDR36 and its role in the normal ocular physiol-
ogy and glaucoma is still unclear, but WDR36 has been iden-
tified as being involved in T cell activation [10].
The purpose of this study was to determine the preva-
lence of WDR36 sequence variants in a cohort of unrelated
German patients with NTG.
METHODS
Screening and selection of patients:  The study population com-
prised a cohort of 112 unrelated white patients with NTG that
included 67 women and 45 men. Their age range was 14-84
years with a mean age of 62.3±15.3. All study patients were
part of a group of 289 patients that had been previously clini-
cally investigated at the University Eye Hospital in Wuerzburg
[11]. Selected from this group for molecular genetic analysis
were 112 patients who had been followed long-term.This was
to ensure diagnosis of NTG with a maximum of certainty.
Patients have been screened for MYOC and OPTN mutations
in a previous study [12]. Glaucoma was defined by the fol-
lowing strict criteria: (1) the presence of typical glaucoma-
tous optic neuropathy with compatible visual field loss (ac-
cording to Aulhorn classification) [13]; (2) open drainage
angles on gonioscopy; and (3) absence of a secondary cause
for glaucomatous optic neuropathy, such as a previously el-
evated intraocular pressure (IOP) after trauma, a period of ste-
roid administration, or uveitis. Patients also did not have evi-
dence of high myopia or congenital ocular abnormality, and
had no other cause than glaucoma for disk changes and visual
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724field loss. A neurological examination was performed in order
to exclude an intracerebral expansion. Sonography was used
to rule out aortic stenosis. Patients with untreated NTG had
IOP measurements that were consistently 21 mmHg or lower
on diurnal testing and during follow-up (IOP readings were
correlated with corneal thickness). Disk size and parameters
were evaluated by means of confocal examination (Heidel-
berg Retina Tomograph). Control DNA samples were obtained
from 50 unrelated subjects of German descent who did not
have a family history of glaucoma. Control individuals were
age matched (mean age 60.5±18.7) and were collected from
the same geographic region as the probands. A diagnosis of
glaucoma was ruled out based on IOP measurements and oph-
thalmoscopy of the optic disk. Written informed consent was
obtained from all participants. This study was approved by
the ethics committees of the University Hospital Tuebingen
and the University Hospital Wuerzburg. It was performed in
accordance with the Helsinki Declaration.
Detection of nucleotide variants by denaturing high per-
formance liquid chromatography:  Patient DNA was extracted
from peripheral blood lymphocytes using a standard salting-
out procedure. Individual exons of the WDR36 gene were
amplified by polymerase chain reaction (PCR) using appro-
priate amplification protocols. Primer pairs used for amplifi-
cation are listed in Table 1. All amplicons containing the cod-
ing exons and neighboring intronic regions of WDR36 were
screened for nucleotide changes with the WAVE denaturing
high-performance liquid chromatography system
(Transgenomic, Inc., Elancourt, France). The PCR products
to be tested were mixed with an equimolar amount of a known
unmutated PCR product to form heteroduplexes. Temperatures
used for analysis are given in Table 2. The resulting DHPLC
trace profiles were examined with the Navigator™ software
(Transgenomic, Inc.). The chromatographs were compared
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TABLE 1. PRIMER PAIRS USED FOR AMPLIFICATION OF WDR36
Exon      Forward (5'-3')               Reverse (5'-3')
----   ---------------------        ------------------------
  1    AATCGTTTCCATCTCCAAGG         AGGACTGCAAGTGCCAAATC
  2    TCTTATGAAGGACAGCATAGCAA      CACTGTGATTCCTCCCAAGG
  3    GGGAAGGACAAGGTGATTTC         TTCCAGAGTGTGCTGGGTAA
  4    GAGGGAGCAGATGAACATGC         CAGGCAAAATCTCTGGCATA
  5    CATTTACAAGTTGCCTCTCATTT      CCTCTGATACAGGGGACCAA
  6    TTCTTAATGAGGTGGCATAGCA       TTGGCAAAGGCATTATTACTTG
  7    TGCTGAGTTTTTCTGCCATC         TTTGCCTTTTACTCCAGTATTCA
  8    TGGATTAAAAGGGAAGAGAGAAGA     TCATCTTCTAGGTTGAAAGCTGAT
  9    AATACCCACTCCCTCCCTTG         ACCCAGACTTCTAAGTCACTCAA
 10    TGCAATCTGGTTTTCCCTTT         GCAACTTTGATGCTAGGAATCTT
 11    CAGTGGTAATAACATCTTTGTTTTGT   ACAGAAGAGCAAAGCCTGATG
 12    TGATTTAGCCGTTCCACAATG        CAATATTATGATGAGAAACCTTG
 13    TGAAGCAATTCATTTATTGTTCTTTT   CCAGCACTTAAAGATTATAC
 14    TTGAATGAAGGAATCACTGTGTG      TGGTAAATTGTGACTTTATGAC
 15    GGCTTAATTTCCCCCAAAGT         ATCGCATCAACTCCCTGAAA
 16    AGGCAGCCTGAATGTTAGTCA        AAGGTTTAGGCATCTCGCTTC
 17    ACTTTTAACATGTTAATTATTTCTG    GTATCTGTGTTAACTTGTGAC
 18    TGCTCAGCATATTCGCACTC         CCCATCACTAGACCCAAAACA
 19    CCATTGAAGAAGGTGTTTTGG        TTGCTCTTCTAATGCCCTCAA
 20    TATCGGCAAGGGTGCTAGAG         AATTCAAGTATCACCCAAAAATG
 21    TTCTGCACTTCTTTACCAAGACC      TGAGAACGCTGATATTTCCTTC
 22    TGTTGCAAGGCATTAGATTTTC       CTGCCCCAGAAGAAGACAAG
 23    GGTGGAGAGGAGTGATGACC         GCTCAAATTCCTGGCTTCAA
Individual exons of the WDR36 gene were amplified by polymerase
chain reaction (PCR) using appropriate amplification protocols.
TABLE 2. AMPLICON SIZES AND OPTIMUM TEMPERATURES FOR
DHPLC ANALYSIS OF ALL INDIVIDUAL WDR36 EXONS
Temperatures used for denaturing high performance liquid chroma-
tography. In the table, bp indicates base pairs.
with the profile of wild-type DNA fragments. Samples with
aberrant profiles were sequenced.
Mutation detection by direct sequencing:  PCR fragments
were purified by ExoSAP-IT treatment (USB, Cleveland, OH),
sequenced using Big Dye Termination chemistry (Applied
Biosystems, Weiterstadt, Germany) and products separated on
a DNA capillary sequencer (ABI 3100 Genetic Analyzer).
Detection of nucleotide variants by restriction fragment
length polymorphism analysis:  A 361 bp PCR product en-
compassing exon 8 of the WDR36 gene was digested with 1 U
725HpyCH4III restriction enzyme (NEB, Beverly, MA). The
N355S missense change resulted in the gain of an HpyCH4III
restriction site that, upon cleavage of the amplicon, produced
two DNA fragments of 251 bp and 110 bp.
A 450 bp PCR product encompassing exon 11 of the
WDR36 gene was digested with 1 U TseI restriction enzyme
(NEB). The A449T missense change resulted in the loss of a
TseI restriction site. Wild-type sequences were cleaved into
two fragments of 229 bp and 221 bp.
A 450 bp PCR product encompassing exon 13 of the
WDR36 gene was digested with 1 U TaqI restriction enzyme
(NEB). The R529Q missense change resulted in the loss of a
TaqI restriction site. Wild-type sequences were cleaved into
two fragments of 232 bp and 218 bp.
A 282 bp PCR product encompassing exon 17 of the
WDR36 gene was digested with 1 U BglI restriction enzyme
(NEB). The D658G missense change resulted in the gain of a
BglI restriction site that, upon cleavage of the amplicon, pro-
duced two DNA fragments of 233 bp and 49 bp. Restriction
digests were analyzed on a 4% agarose gel.
RESULTS
 We screened the complete coding sequences plus flanking
intron/UTR sequences of the WDR36 gene by denaturing high
performance liquid chromatography (DHPLC) and subsequent
sequencing in 112 patients with NTG. In addition, we per-
formed RFLP analysis for four known sequence alterations
that were judged in a previous study to be disease-causing
mutations [9]. Of those four, we were able to identify three by
RFLP analysis as well as with DHPLC and subsequent se-
quencing, namely A449T (found in two subjects), R529Q
(found in one subject), and D658G (found in one subject),
respectively (Figure 1 and Table 3). We were not able to de-
tect any of these changes in 50 controls using DHPLC and
RFLP analysis.
DHPLC analysis and subsequent sequencing also identi-
fied four additional nonsynonymous nucleotide changes,
namely P31T, D33E, A163V, and H212P which were not
present in 50 controls. The latter three have already been de-
scribed [9,14], whereas this is the first report of P31T.
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Figure 1. Comparison of three mutation detection systems used in this study.  A: Denaturing high performance liquid chromatography profiles
of mutant (red) and wild-type (green) alleles of three WDR36 missense mutations. B: RFLP analysis. The following abbreviations were used:
100 bp ladder (M), restriction digest of mutant PCR product (Mut), and restriction digest of control PCR product (WT). C: DNA sequence
analysis.
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Figure 2. Amino acid alignment and evolutionary conservation of non-synonymous changes identified in this study.  Partial amino acid
sequences of WDR36 protein orthologs from five different species were aligned to show possible conservation. Grey boxes highlight affected
residues. P31T and D33E are not shown as the very NH2-terminal part of the human WDR36 protein was not conserved.
TABLE 3. FREQUENCIES, LOCALIZATION, AND PUTATIVE FUNCTIONAL EFFECT OF IDENTIFIED WDR36 SEQUENCE VARIANTS
Sequence variants identified in the WDR36 gene. The “Nucleotide change” column is based on GenBank accession number NM_139281 and
the “Prediction of functional effect” column is according to PolyPhen. In the table, ND refers to not determined.
727DHPLC screening and subsequent sequencing also re-
vealed several synonymous polymorphisms (Q197Q, K564K,
V714V, V727V) as well as 11 intronic alterations (Table 3).
Neither a deletion/insertion nor a sequence alteration close to
splice donor/acceptor sites change was found.
Four patients harbored a potentially causative mutation
in the OPTN gene or MYOC gene as was found in a previous
study [12]. These patients did not show sequence variants in
the WDR36 gene.
DISCUSSION
 This study describes mutational screening in the WDR36 gene
in a large cohort of German patients with the NTG subtype of
POAG. The primary aim of our study was to evaluate the preva-
lence of previously described mutations classified as disease
causing [9]. Therefore, two different mutation-screening tech-
niques (DHPLC and RFLP) were used to make sure that all
four mutations (N355S, A449T, R529Q, and D658G) were
detected.
None of our patients had the N355S mutation described
by Monemi and coworkers [9]. Instead, we identified one pa-
tient who harbored the R529Q mutation that has already been
described in two independent studies [9,14]. According to the
prediction program PolyPhen, this particular change lies in a
highly conserved region and possibly has a damaging effect
(Table 3 and Figure 2). In addition, we identified two patients
with NTG who carried the A449T sequence variant. This mu-
tation is not part of a known protein motif. It was not con-
served and is therefore benign according to the PolyPhen pre-
diction. The D658G mutation noted in 3 out of 272 sporadic
cases in the Monemi study was observed in one patient in the
NTG group. In the former study this change was shown to be
not present in 238 controls, whereas a case-control study on
this particular variant in Australian patients demonstrated an
equal distribution in both patients and controls [15]. Although
this mutation leads to a conservative exchange of two polar
and acidic residues, PolyPhen predicts this change to be prob-
ably damaging due to the high conservation between species
(Figure 2).
In addition to the aforedescribed disease-causing muta-
tions, we were able to identify sequence variants previously
classified as disease-susceptibility mutations, namely D33E,
A163V, and H212P [9,14]. We also noted one nonsynonymous
nucleotide change (P31E) that has not been reported before. It
was found in one patient in the NTG group and was not present
in the control population. As the proline residue is not con-
served between species (data not shown) and is not located in
any known protein motif of WDR36, this change is probably
benign.
Although our patient and control cohort numbers were
too small for a statistical analysis to determine whether the
sequence variants we identified might be related to the dis-
ease, our results indicate that sequence variants of the WDR36
gene already described to be disease-causing are only rare
causes of unrelated NTG in the German population.
Apart from the findings of our study concerning WDR36
sequence variants, we observed that the results of the DHPLC
screening in those exons that harbored already described mu-
tations were consistent with the results of RFLP analysis (Fig-
ure 1). In addition, we identified several exonic and intronic
polymorphisms by using DHPLC and subsequent sequenc-
ing. Therefore we reason that screening of the WDR36 gene
with DHPLC gives rather reliable results compared with the
hands-on time. Direct sequencing still represents the gold stan-
dard in mutation screening, and other screening mechanisms,
such as DHPLC, are not as sensitive. Nevertheless, we are
convinced that our screening procedure using DHPLC and
RFLP gave comparable good detection rates. From our study
it seems likely that DHPLC gives false positive results rather
than false negative ones. Yet, we have to consider that we may
have missed some nucleotide changes that could be associ-
ated with the NTG phenotype in our patients. In addition, as
we only screened for mutations in exonic and flanking intron
sequences, it is possible that a proportion of our patients carry
mutations in the promoter region or in other regulatory se-
quences of WDR36. Screening with either DHPLC or direct
sequencing does not reveal gross insertions or deletions that
may be responsible for the phenotype.
Our study indicates that WDR36 sequence variants are
only rare causes of unrelated NTG in the German population.
In a previous study [12], we showed this also holds true for
the other two POAG-associated genes MYOC and OPTN. As
early diagnosis is critical for successful treatment of glaucoma,
defining the genetic basis of hereditary forms of glaucoma is
an important step towards a presymptomatic screening of
people at risk. However, a routine genetic testing for the three
known POAG-associated genes seems to be of limited value
due to the low prevalence of disease-causing mutations.
A considerable number of studies dealing with the genet-
ics of glaucoma have shown that only a small proportion of
glaucoma cases are due to monogenic forms. The vast major-
ity of cases are inherited as a complex trait. Therefore, ge-
nome-wide association studies might be a better strategy to
use in defining genetic profiles for those at risk for develop-
ing glaucoma.
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